AMGN path to recovery and growth

Amgen's (AMGN) growth trajectory has been bolstered by strong pipeline performance and recent regulatory approvals, driving analyst price target increases and positive market sentiment. On June 10, Morgan Stanley raised its price target following a robust start for Uplizna, while Piper Sandler and Morgan Stanley highlighted Amgen's pipeline strength and obesity drug potential on June 12. Amgen's shares have surpassed the average analyst target price, reaching $243.12 on June 16. The company's recent EC marketing authorization for IMDYLLTRA® further solidifies its growth prospects.

Amgen's positive developments have positively impacted the biotechnology and pharmaceutical sectors. The company's strong pipeline and regulatory approvals have boosted investor confidence in its growth potential, driving demand for its shares and pushing up its valuation. Amgen's dividend yield of 2.85% has also made it an attractive option for income-oriented investors, contributing to its inclusion in lists of high-yield stocks and set-it-and-forget-it stocks.

Investors should watch for Amgen's upcoming Q2 earnings release on July 28, 2026, to gauge the financial impact of its recent pipeline progress and regulatory approvals. Additionally, the company's Phase 3 VESALIUS-CV subgroup results for Repatha in high-risk diabetes patients, announced on June 7, 2026, will provide further insight into the drug's potential in this indication. Lastly, investors should monitor Amgen's obesity drug development pipeline, as positive data or regulatory approvals in this area could drive further growth and valuation increases.